Stem Cells Could Potentially Treat Eczema, Atopic Dermatitis
Approximately half of patients who received a high dose of the stem cells had reduced symptoms.
Findings from a recent study suggests that stem cells from umbilical cord blood could be a potentially effective treatment for moderate-to-severe eczema or atopic dermatitis.
The study, published by STEM CELLS, included 32 patients who either received low doses or high doses of the stem cells subcutaneously.
Researchers found that at 12 weeks, 55% of patients receiving a high dose had a reduced Eczema Area and Severity Index score.
Patients receiving a high dose of the stem cells had a significantly reduced rate of immune-related markers of atopic dermatitis, according to the study.
"This study is a first-in-class study demonstrating that adults with moderate-to-severe atopic dermatitis responded to a treatment of stem cells derived from umbilical cord blood," concluded study senior author Tae-Yoon Kim, PhD. "The single treatment of stem cells in patients resulted in the significant and persistent improvement in disease symptoms throughout the follow-up period of 12 weeks."
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025